Pfizer Financial Statements From 2010 to 2022

PFE
 Stock
  

USD 48.29  1.66  3.32%   

Pfizer financial statements provide useful quarterly and yearly information to potential Pfizer Inc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pfizer financial statements helps investors assess Pfizer's valuation, profitability, and current liquidity needs.
There are over one hundred sixteen available trending fundamental ratios for Pfizer Inc, which can be analyzed over time and compared to other ratios. Please make sure to check out all of Pfizer's recent performance against the performance from 2010 to 2022 to make sure the company is sustainable down the road.
Pfizer Revenue Per Employee is projected to increase significantly based on the last few years of reporting. The past year's Revenue Per Employee was at 1.03 Million. The current year Average Assets is expected to grow to about 149.9 B, whereas Earnings before Tax are forecasted to decline to about 18.5 B.
  
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer main balance sheet or income statement drivers, such as Direct Expenses of 33.3 B, Consolidated Income of 17 B or Cost of Revenue of 9.4 B, as well as many exotic indicators such as Interest Coverage of 15.54, Long Term Debt to Equity of 0.45 or Calculated Tax Rate of 9.19. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules. It can also supplement Pfizer's financial leverage analysis and stock options assessment as well as various Pfizer Technical models . Please check the analysis of Pfizer Correlation against competitors.

Pfizer Revenues

75.5 Billion

Pfizer Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets196 B181.5 B175.4 B
Decreasing
Stable
Cash and Equivalents2.7 B1.9 B2.9 B
Decreasing
Slightly volatile
Investments27.9 B25.8 B32.3 B
Decreasing
Slightly volatile
Investments Current7.9 B7.7 B18.3 B
Decreasing
Slightly volatile
Investments Non Current14.7 B18.1 B13.6 B
Increasing
Stable
Property Plant and Equipment Net12.9 B12.6 B14.1 B
Decreasing
Slightly volatile
Inventory7.1 B7.5 B7.5 B
Decreasing
Very volatile
Tax Assets5.8 B4.9 B6.7 B
Decreasing
Slightly volatile
Trade and Non Trade Receivables8.4 B7.9 B9.4 B
Decreasing
Slightly volatile
Trade and Non Trade Payables4.8 B4.9 B4.1 B
Increasing
Slightly volatile
Goodwill and Intangible Assets84.3 B84.6 B92.3 B
Decreasing
Stable
Total Liabilities113.8 B104.3 B102.8 B
Decreasing
Very volatile
Shareholders Equity82.2 B77.2 B72.6 B
Decreasing
Slightly volatile
Accumulated Retained Earnings Deficit98.2 B112.3 B77.5 B
Increasing
Slightly volatile
Accumulated Other Comprehensive Income(11.3 B)(10.5 B)(8.2 B)
Decreasing
Slightly volatile
Current Assets60.1 B59.7 B50.4 B
Decreasing
Slightly volatile
Assets Non Current117.1 B121.2 B125.5 B
Decreasing
Stable
Current Liabilities35.1 B42.7 B30.3 B
Increasing
Slightly volatile
Liabilities Non Current62.8 B60.1 B71.3 B
Decreasing
Slightly volatile
Tax Liabilities20.5 B16.8 B25.8 B
Decreasing
Slightly volatile
Total Debt55.8 B60 B45 B
Increasing
Slightly volatile
Debt Current20.1 B18.6 B10.6 B
Increasing
Slightly volatile
Debt Non Current31.3 B32.4 B33.3 B
Decreasing
Stable
Shareholders Equity USD61 B56.8 B69.5 B
Decreasing
Slightly volatile
Cash and Equivalents USD1.2 B1.2 B2.7 B
Decreasing
Slightly volatile
Total Debt USD55.8 B60 B45 B
Increasing
Slightly volatile
Accounts Payable4.7 B5.6 B4.2 B
Increasing
Slightly volatile
Receivables11.8 B11.5 B10.1 B
Decreasing
Slightly volatile
Inventories7.9 B9.1 B7.5 B
Increasing
Slightly volatile

Pfizer Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues75.5 B81.3 B58 B
Increasing
Very volatile
Cost of Revenue9.4 B9.2 B10.3 B
Decreasing
Very volatile
Selling General and Administrative Expense13.2 B12.9 B14.6 B
Decreasing
Slightly volatile
Research and Development Expense7.5 B7.8 B7.9 B
Increasing
Stable
Operating Expenses28.5 B28.7 B30.6 B
Decreasing
Stable
Income Tax Expense1.1 B1.2 B1.2 B
Decreasing
Stable
Consolidated Income17 B18.7 B13.8 B
Increasing
Slightly volatile
Net Income to Non Controlling Interests37.4 M33.4 M34.3 M
Increasing
Very volatile
Net Income23.7 B22 B14 B
Increasing
Slightly volatile
Net Income Common Stock17 B18.7 B13.8 B
Increasing
Slightly volatile
Weighted Average Shares6.7 B5.6 B6.5 B
Decreasing
Slightly volatile
Weighted Average Shares Diluted6.8 B5.7 B6.5 B
Decreasing
Slightly volatile
Earning Before Interest and Taxes EBIT18.5 B20.3 B15 B
Increasing
Stable
Revenues USD47.1 B46.6 B51.6 B
Decreasing
Slightly volatile
Net Income Common Stock USD17 B18.7 B13.8 B
Increasing
Slightly volatile
Earning Before Interest and Taxes USD18.5 B20.3 B15 B
Increasing
Stable
Gross Profit37.7 B37.4 B41.4 B
Decreasing
Slightly volatile
Operating Income22.3 B20.7 B13.1 B
Increasing
Slightly volatile
Direct Expenses33.3 B30.8 B14.6 B
Increasing
Slightly volatile

Pfizer Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals(13.5 B)(12.5 B)(9.8 B)
Decreasing
Very volatile
Net Cash Flow Investment Acquisitions and Disposals11.5 B10.7 B5.6 B
Increasing
Slightly volatile
Issuance Repayment of Debt Securities 8.5 B7.9 B4.3 B
Increasing
Stable
Net Cash Flow from Investing(23.1 B)(22.5 B)(5.6 B)
Decreasing
Slightly volatile
Net Cash Flow from Operations35.2 B32.6 B18.5 B
Increasing
Slightly volatile
Effect of Exchange Rate Changes on Cash (31.1 M)(28.8 M)(116.8 M)
Increasing
Very volatile
Net Cash Flow or Change in Cash and Cash Equivalents121.4 M112.5 M(18.1 M)
Decreasing
Very volatile
Share Based Compensation783.5 M825.7 M657.9 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion5.6 B5.4 B6.2 B
Decreasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share4.233.922.2709
Increasing
Slightly volatile
Earnings per Diluted Share4.153.852.2379
Increasing
Slightly volatile
Earnings per Basic Share USD2.873.362.2299
Increasing
Slightly volatile
Dividends per Basic Common Share1.481.661.1896
Increasing
Slightly volatile
Return on Average Equity33.7731.301819.7061
Increasing
Slightly volatile
Return on Average Assets14.1313.09488.1083
Increasing
Slightly volatile
Return on Invested Capital0.220.240.1672
Increasing
Slightly volatile
Gross Margin77.6762.084277.7181
Decreasing
Slightly volatile
Profit Margin24.1827.039723.6653
Increasing
Stable
EBITDA Margin32.6636.002932.5746
Increasing
Slightly volatile
Return on Sales0.350.390.2866
Increasing
Stable
Asset Turnover0.390.48430.3278
Increasing
Slightly volatile
Payout Ratio0.670.570.6193
Decreasing
Very volatile
Enterprise Value over EBITDA13.9112.9612.5033
Increasing
Slightly volatile
Enterprise Value over EBIT19.9717.2518.4787
Increasing
Stable
Price to Earnings Ratio18.415.4317.3448
Increasing
Very volatile
Sales per Share15.6614.51319.3726
Increasing
Slightly volatile
Price to Sales Ratio4.654.853.9582
Increasing
Slightly volatile
Price to Book Value3.643.953.0106
Increasing
Slightly volatile
Debt to Equity Ratio0.50.49790.5742
Increasing
Slightly volatile
Dividend Yield0.03270.03330.0352
Decreasing
Slightly volatile
Current Ratio1.731.39891.7242
Decreasing
Slightly volatile
Free Cash Flow per Share5.755.33282.69
Increasing
Slightly volatile
Book Value per Share10.0410.210.9714
Decreasing
Slightly volatile
Tangible Assets Book Value per Share11.5411.8712.5684
Decreasing
Slightly volatile
Total Assets Per Share28.632.291127.6438
Increasing
Slightly volatile
Cash Flow Per Share6.265.79723.0241
Increasing
Slightly volatile
Return on Investment20.4318.937311.6528
Increasing
Slightly volatile
Operating Margin22.6225.476121.9304
Increasing
Very volatile
Calculated Tax Rate9.197.6188.9691
Decreasing
Slightly volatile
Receivables Turnover6.838.37635.8319
Increasing
Slightly volatile
Inventory Turnover3.893.60371.8555
Increasing
Slightly volatile
PPandE Turnover4.615.64853.941
Increasing
Slightly volatile
Cash and Equivalents Turnover47.0543.609427.5073
Increasing
Slightly volatile
Accounts Payable Turnover16.5716.443413.8919
Decreasing
Slightly volatile
Accrued Expenses Turnover15.8115.051913.7963
Decreasing
Slightly volatile
Interest Coverage15.5416.501212.1273
Increasing
Stable
Long Term Debt to Equity0.450.46880.4708
Increasing
Slightly volatile
Quick Ratio1.210.99711.1943
Decreasing
Slightly volatile
Net Current Assets as percentage of Total Assets11.389.379811.1474
Decreasing
Slightly volatile
Revenue to Assets0.370.44790.3277
Increasing
Stable

Pfizer Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax18.5 B20.3 B15 B
Increasing
Stable
Earnings Before Interest Taxes and Depreciation Amortization EBITDA23.1 B29.3 B18.7 B
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD19.6 B21.3 B20.5 B
Decreasing
Very volatile
Market Capitalization242.5 B249.4 B206.4 B
Increasing
Slightly volatile
Enterprise Value295 B306.7 B248 B
Increasing
Slightly volatile
Invested Capital80.2 B78.3 B89.1 B
Decreasing
Slightly volatile
Average Equity59.9 B55.5 B68.6 B
Decreasing
Slightly volatile
Average Assets149.9 B146.1 B167.1 B
Decreasing
Slightly volatile
Invested Capital Average79.2 B75.8 B89.2 B
Decreasing
Slightly volatile
Tangible Asset Value70 B66.1 B79.7 B
Decreasing
Slightly volatile
Free Cash Flow10.7 BB13.5 B
Decreasing
Slightly volatile
Working Capital(4.2 B)(4.1 B)14.8 B
Decreasing
Slightly volatile
Revenue Per Employee1.1 MM666.9 K
Increasing
Slightly volatile
Net Income Per Employee300.2 K278.2 K162.9 K
Increasing
Slightly volatile

Pfizer Fundamental Market Drivers

Forward Price Earnings9.08
Short Percent Of Float1.20%
Average Daily Volume Last 10 Day20.03M
Shares Short Prior Month76.98M
Average Daily Volume In Three Month21.18M
Date Short Interest15th of July 2022
Fifty Day Average51.27
Two Hundred Day Average51.43

Pfizer Upcoming Events

Upcoming Quarterly Report8th of February 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End8th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Pfizer Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Pfizer income statement, its balance sheet, and the statement of cash flows. Pfizer investors use historical funamental indicators, such as Pfizer's revenue or net income, to determine how well the company is positioned to perform in the future. Although Pfizer investors may use each financial statement separately, they are all related. The changes in Pfizer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pfizer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pfizer Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pfizer. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Cost of Revenue9.2 B9.4 B
Revenues81.3 B75.5 B
Revenue to Assets 0.45  0.37 
Revenue Per EmployeeM1.1 M
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people.

Pfizer Investors Sentiment

The influence of Pfizer's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Pfizer. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Pfizer's public news can be used to forecast risks associated with investment in Pfizer. The trend in average sentiment can be used to explain how an investor holding Pfizer can time the market purely based on public headlines and social activities around Pfizer Inc. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Pfizer's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pfizer's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Pfizer's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Pfizer.

Pfizer Implied Volatility

    
  25.9  
Pfizer's implied volatility exposes the market's sentiment of Pfizer Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Pfizer's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Pfizer stock will not fluctuate a lot when Pfizer's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.

Currently Active Assets on Macroaxis

Please check the analysis of Pfizer Correlation against competitors. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.